


Response Under 37 C.F.R. 1.116 - Expedited Procedure
Examining Group 1643

18. (Twice Amended.) A purified polypeptide comprising an amino acid sequence selected from the group consisting of:

- a) an amino acid sequence of SEQ ID NO:1,
- a naturally-occurring amino acid sequence having at least 95% sequence identity to the sequence of SEQ ID NO:1, wherein said amino acid sequence encodes a polypeptide whose expression is upregulated by 2,3,7,8-Tetrachlorodibenzo-p-dioxin,
- a biologically-active fragment of the amino acid sequence of SEQ ID NO:1, wherein said fragment encodes a polypeptide whose expression is upregulated by 2,3,7,8-Tetrachlorodibenzo-p-dioxin, and
- d) an immunologically active fragment of the amino acid sequence of SEQ ID NO:1 wherein said fragment generates an antibody that specifically binds to the polypeptide encoded by SEQ ID NO:1.
- 19. An isolated polypeptide of claim 18, having a sequence of SEQ ID NO:1.
- 20. An isolated polynucleotide encoding a polypeptide of claim 18.
- 21. An isolated polynucleotide encoding a polypeptide of claim 19.
- 22. An isolated polynucleotide of claim 21, having a sequence of SEQ ID NO:2.
- An expression vector comprising a promoter sequence operably linked to a polynucleotide of claim 20.
  - 24. A host cell transformed with a recombinant polynucleotide of claim 23.
  - 25. A method for producing a polypeptide of claim 18, the method comprising:
  - a) culturing a host cell under conditions suitable for expression of the polypeptide,
     wherein said host cell is transformed with an expression vector, and said



Response Under 37 C.F.R. 1.116 - Expedited Procedure
Examining Group 1643

expression vector comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 18, and

- b) recovering the polypeptide so expressed.
- 26. A method of claim 25, wherein the polypeptide has the sequence of SEQ ID NO:1.
- 27. An isolated polynucleotide comprising a sequence selected from the group consisting of:
  - a) a polynucleotide sequence of SEQ ID NO:2,
  - a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:2,
  - c) a polynucleotide sequence complementary to a),
  - d) a polynucleotide sequence complementary to b) and
  - e) a ribonucleotide equivalent of a)-d).
- An isolated polynucleotide comprising at least 60 contiguous nucleic acids of claim
- 29. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 27, the method comprising:
  - a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
  - detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
- 30. A method of claim 29, wherein the probe comprises at least 60 contiguous nucleotides.

Response Under 37 C.F.R. 1.116 - Expedited Procedure

Examining Group 1643

31. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 27, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
- An isolated antibody which specifically binds to a polypeptide of claim 18.
- 33. A pharmaceutical composition comprising an effective amount of a polypeptide of claim 18 and a pharmaceutically acceptable excipient.
- 34. A pharmaceutical composition of claim 34, wherein the polypeptide has the sequence of SEQ ID NO:1.
- 35. A method for treating a disorder which is associated with decreased expression of the polypeptide of claim 18 comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition comprising said polypeptide and a pharmaceutically acceptable excipient.
- 36. A purified agonist which specifically binds to and modulates the activity of the polypeptide of claim 18.
- 37. A purified antagonist which specifically binds to and inhibits the activity of the polypeptide of claim 18.
- 38. A pharmaceutical composition comprising the antagonist of claim 37 in conjunction with a suitable pharmaceutical carrier.
  - 39. A method for treating a disorder which is associated with increased expression of the

Response Under 37 C.F.R. 1.116 - Expedited Procedure

Examining Group 1643

polypeptide of claim 18 comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition comprising an antagonist which specifically binds to and inhibits the activity of said polypeptide.

- 40. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 18, the method comprising:
  - exposing a sample comprising a polypeptide of claim 18 to a compound, and a)
  - b) detecting agonist activity in the sample.
- 41. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 18, the method comprising:
  - exposing a sample comprising a polypeptide of claim 18 to a compound, and a)
  - b) detecting antagonist activity in the sample.
- 42. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 21, the method comprising:
  - a) exposing a sample comprising the target polynucleotide to a compound, and
  - b) detecting altered expression of the target polynucleotide.